Outcome after intensity modulated radiotherapy for anaplastic thyroid carcinoma

BMC Cancer

Xiayun He²  Duanshu Li¹  Chaosu Hu²  Zhuoying Wang¹  Hongmei Ying²  Yi Wu¹ 

[1] Department of Head and Neck Surgery, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China

[2] Department of Radiation Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China

关键词: Distant metastases;    Locoregional control;    Intensity modulated radiotherapy;    ATC;    Anaplastic thyroid carcinoma;   

Others  :  858923
DOI  :  10.1186/1471-2407-14-235

 received in 2013-01-29, accepted in 2014-03-25,  发布年份 2014

【 摘 要 】

Background

Anaplastic thyroid carcinoma (ATC) is a malignancy with one of the highest fatality rates. We reviewed our recent clinical experience with intensity modulated radiotherapy (IMRT) combined with surgery and chemotherapy for the management of ATC.

Methods

13 patients with ATC who were treated by IMRT in our institution between October 2008 and February 2011, have been analyzed. The target volume for IMRT was planned to include Gross tumor volume (GTV): primary tumor plus any N + disease (66 Gy/33 F/6.6 W), with elective irradiation of thyroid bed, bilateral level II through VI and mediastinal lymph nodes to the level of the carina (54-60 Gy). Seven patients received surgical intervention and eleven patients had chemotherapy.

Results

The median radiotherapy dose to GTV was 60 Gy/30 fractions/6 weeks. The median survival time of the 13 patients was 9 months. The direct causes of death were distant metastases (75%) and progression of the locoregional disease (25%). Ten patients were spared dyspnea and tracheostomy because their primary neck lesion did not progress.

Conclusion

The results showed that IMRT combined by surgery and chemotherapy for ATC might be beneficial to improve locoregional control. Further new therapies are needed to control metastases.

【 授权许可】

   
2014 He et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Baroli A, Pedrazzini L, Lomuscio G, Marzoli L: Anaplastic thyroid carcinoma. Practical aspects of multimodal therapy and data emerging from a 40-year experience at a single Italian institution. Minerva Endocrinol 2010, 35:9-16.
• [2]Roche B, Larroumets G, Dejax C, Kwiatkowsi F, Desbiez F, Thieblot P, Tauveron I: Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC): comparison with the literature. Ann Endocrinol(Paris) 2010, 71:38-45.
• [3]Chen J, Tward JD, Shrieve DC, Hitchcock YJ: Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 2008, 31:460-464.
• [4]Ito K, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M, Ito T, Koyama H, Kanai T, Maeno K, Mochizuki Y, Amano J: Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck 2012, 34:230-237.
• [5]Tashima L, Mitzner R, Durvesh S, Goldenberg D: Dyspnea as a prognostic factor in anaplastic thyroid carcinoma. Eur Arch Otorhinolaryngol 2012, 269:1251-1255.
• [6]Smallridge RC: Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2012, 97:2566-2572.
• [7]Burnison CM: Lim S: Multimodal approach to anaplastic thyroid cancer. Oncology (Williston Park) 2012, 26:378-384.
• [8]Lim SM, Shin SJ, Chung WY, Park CS, Nam KH, Kang SW, Keum KC, Kim JH, Cho JY, Hong YK, Cho BC: Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J 2012, 53:352-357.
• [9]Wein RO, Weber RS: Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg 2011, 19:113-118.
• [10]Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, Ito K, Ito K: Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011, 21:1183-1189.
• [11]Derbel O, Limem S, Ségura-Ferlay C, Lifante JC, Carrie C, Peix JL, Borson-Chazot F, Bournaud C, Droz JP, de la Fouchardière C: Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 2011, 11:469. BioMed Central Full Text
• [12]Swaak-Kragten AT, de Wilt JH: Schmitz Pl: Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma treatment outcome in 75 patients. Radiother Oncol 2009, 92:100-104.
• [13]Goutsouliak V, Hay JH: Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol (R Coll Radiol) 2005, 17:75-78.
• [14]Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC: Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011, 21:25-30.
• [15]Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S: Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 2012, 36:1247-1254.
• [16]Tanaka K, Sugitani I, Fujimoto Y: A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report. Jpn J Clin Oncol 2011, 41:1074-1078.
• [17]Perri F, Lorenzo GD, Scarpati GD, Buonerba C: Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2011, 10:150-157.
• [18]Siironen P, Hagström J, Mäenpää HO, Louhimo J, Heikkilä A, Heiskanen I, Arola J, Haglund C: Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology 2010, 79:400-408.
• [19]Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, Matsuzuka F, Miyauchi A: Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 2010, 20:7-14.
• [20]Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ: Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 2005, 131:585-590.
• [21]Pudney D, Lau H, Ruether JD, Falck V: Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid 2007, 17:1243-1250.
• [22]Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B, Raderer M: High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 2010, 95:E54-E57.